Cargando…

The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers

Overlapping histological features between benign and malignant lesions and a lack of firm diagnostic criteria for malignancy result in high rates of inter-observer variation in the diagnosis of melanocytic lesions. We aimed to investigate the differential expression of five miRNAs (21, 200c, 204, 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Quiohilag, Katherine, Caie, Peter, Oniscu, Anca, Brenn, Thomas, Harrison, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320036/
https://www.ncbi.nlm.nih.gov/pubmed/32388720
http://dx.doi.org/10.1007/s00428-020-02817-5
_version_ 1783551166188093440
author Quiohilag, Katherine
Caie, Peter
Oniscu, Anca
Brenn, Thomas
Harrison, David
author_facet Quiohilag, Katherine
Caie, Peter
Oniscu, Anca
Brenn, Thomas
Harrison, David
author_sort Quiohilag, Katherine
collection PubMed
description Overlapping histological features between benign and malignant lesions and a lack of firm diagnostic criteria for malignancy result in high rates of inter-observer variation in the diagnosis of melanocytic lesions. We aimed to investigate the differential expression of five miRNAs (21, 200c, 204, 205, and 211) in benign naevi (n = 42), dysplastic naevi (n = 41), melanoma in situ (n = 42), and melanoma (n = 42) and evaluate their potential as diagnostic biomarkers of melanocytic lesions. Real-time PCR showed differential miRNA expression profiles between benign naevi; dysplastic naevi and melanoma in situ; and invasive melanoma. We applied a random forest machine learning algorithm to classify cases based on their miRNA expression profiles, which resulted in a ROC curve analysis of 0.99 for malignant melanoma and greater than 0.9 for all other groups. This indicates an overall very high accuracy of our panel of miRNAs as a diagnostic biomarker of benign, dysplastic, and malignant melanocytic lesions. However, the impact of variable lesion percentage and spatial expression patterns of miRNAs on these real-time PCR results was also considered. In situ hybridisation confirmed the expression of miRNA 21 and 211 in melanocytes, while demonstrating expression of miRNA 205 only in keratinocytes, thus calling into question its value as a biomarker of melanocytic lesions. In conclusion, we have validated some miRNAs, including miRNA 21 and 211, as potential diagnostic biomarkers of benign, dysplastic, and malignant melanocytic lesions. However, we also highlight the crucial importance of considering tissue morphology and spatial expression patterns when using molecular techniques for the discovery and validation of new biomarkers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00428-020-02817-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7320036
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-73200362020-07-01 The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers Quiohilag, Katherine Caie, Peter Oniscu, Anca Brenn, Thomas Harrison, David Virchows Arch Original Article Overlapping histological features between benign and malignant lesions and a lack of firm diagnostic criteria for malignancy result in high rates of inter-observer variation in the diagnosis of melanocytic lesions. We aimed to investigate the differential expression of five miRNAs (21, 200c, 204, 205, and 211) in benign naevi (n = 42), dysplastic naevi (n = 41), melanoma in situ (n = 42), and melanoma (n = 42) and evaluate their potential as diagnostic biomarkers of melanocytic lesions. Real-time PCR showed differential miRNA expression profiles between benign naevi; dysplastic naevi and melanoma in situ; and invasive melanoma. We applied a random forest machine learning algorithm to classify cases based on their miRNA expression profiles, which resulted in a ROC curve analysis of 0.99 for malignant melanoma and greater than 0.9 for all other groups. This indicates an overall very high accuracy of our panel of miRNAs as a diagnostic biomarker of benign, dysplastic, and malignant melanocytic lesions. However, the impact of variable lesion percentage and spatial expression patterns of miRNAs on these real-time PCR results was also considered. In situ hybridisation confirmed the expression of miRNA 21 and 211 in melanocytes, while demonstrating expression of miRNA 205 only in keratinocytes, thus calling into question its value as a biomarker of melanocytic lesions. In conclusion, we have validated some miRNAs, including miRNA 21 and 211, as potential diagnostic biomarkers of benign, dysplastic, and malignant melanocytic lesions. However, we also highlight the crucial importance of considering tissue morphology and spatial expression patterns when using molecular techniques for the discovery and validation of new biomarkers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00428-020-02817-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-05-09 2020 /pmc/articles/PMC7320036/ /pubmed/32388720 http://dx.doi.org/10.1007/s00428-020-02817-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Quiohilag, Katherine
Caie, Peter
Oniscu, Anca
Brenn, Thomas
Harrison, David
The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers
title The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers
title_full The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers
title_fullStr The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers
title_full_unstemmed The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers
title_short The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers
title_sort differential expression of micro-rnas 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320036/
https://www.ncbi.nlm.nih.gov/pubmed/32388720
http://dx.doi.org/10.1007/s00428-020-02817-5
work_keys_str_mv AT quiohilagkatherine thedifferentialexpressionofmicrornas21200c204205and211inbenigndysplasticandmalignantmelanocyticlesionsandcriticalevaluationoftheirroleasdiagnosticbiomarkers
AT caiepeter thedifferentialexpressionofmicrornas21200c204205and211inbenigndysplasticandmalignantmelanocyticlesionsandcriticalevaluationoftheirroleasdiagnosticbiomarkers
AT oniscuanca thedifferentialexpressionofmicrornas21200c204205and211inbenigndysplasticandmalignantmelanocyticlesionsandcriticalevaluationoftheirroleasdiagnosticbiomarkers
AT brennthomas thedifferentialexpressionofmicrornas21200c204205and211inbenigndysplasticandmalignantmelanocyticlesionsandcriticalevaluationoftheirroleasdiagnosticbiomarkers
AT harrisondavid thedifferentialexpressionofmicrornas21200c204205and211inbenigndysplasticandmalignantmelanocyticlesionsandcriticalevaluationoftheirroleasdiagnosticbiomarkers
AT quiohilagkatherine differentialexpressionofmicrornas21200c204205and211inbenigndysplasticandmalignantmelanocyticlesionsandcriticalevaluationoftheirroleasdiagnosticbiomarkers
AT caiepeter differentialexpressionofmicrornas21200c204205and211inbenigndysplasticandmalignantmelanocyticlesionsandcriticalevaluationoftheirroleasdiagnosticbiomarkers
AT oniscuanca differentialexpressionofmicrornas21200c204205and211inbenigndysplasticandmalignantmelanocyticlesionsandcriticalevaluationoftheirroleasdiagnosticbiomarkers
AT brennthomas differentialexpressionofmicrornas21200c204205and211inbenigndysplasticandmalignantmelanocyticlesionsandcriticalevaluationoftheirroleasdiagnosticbiomarkers
AT harrisondavid differentialexpressionofmicrornas21200c204205and211inbenigndysplasticandmalignantmelanocyticlesionsandcriticalevaluationoftheirroleasdiagnosticbiomarkers